Comparative Pharmacology
Head-to-head clinical analysis: AVALIDE versus NAQUIVAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVALIDE versus NAQUIVAL.
AVALIDE vs NAQUIVAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avalide is a combination of an angiotensin II receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide). Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
NAQUIVAL (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing electrolyte reabsorption and increasing urine output, thereby lowering blood pressure and reducing edema.
AVALIDE (irbesartan/hydrochlorothiazide) is available as tablets containing 150/12.5 mg, 300/12.5 mg, or 300/25 mg. The typical starting dose is 150/12.5 mg once daily, titrated to 300/12.5 mg once daily as needed. Maximum dose is 300/25 mg once daily.
Adults: 0.1 mg/kg IV bolus, then 0.1 mg/kg/hour continuous IV infusion, titrated to clinical response. Maximum 0.5 mg/kg/hour.
None Documented
None Documented
Irbesartan: 11-15 h (terminal), HCTZ: 6-15 h (terminal). Clinical context: Steady state reached in 3-5 days; allows once-daily dosing.
Terminal elimination half-life: 14-16 hours (healthy adults). Extended to 26-35 hours in heart failure or hepatic cirrhosis due to reduced clearance.
Renal: HCTZ ~70% unchanged; Irbesartan ~20% unchanged, remainder as metabolites via biliary (60%) and renal (20%). Combined: Renal ~50%, biliary/fecal ~50%.
Renal: 50-60% as unchanged drug; fecal: <10% (biliary); remainder as metabolites (80% renal, 10% fecal).
Category C
Category C
ARB and Thiazide Diuretic Combination
Thiazide Diuretic Combination